Old Drugs in a New Package: Future of Cancer Nanomedicine
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: 25 October 2024 | Viewed by 3635
Special Issue Editors
Interests: genetically engineered materials; nanotechnology; drug and gene delivery; anti-cancer therapeutics
Special Issue Information
Dear Colleagues,
Seminal research on cancer nanomedicine in last several decades has begun to pay dividends in the clinic, allowing for the delivery of cancer drugs with enhanced systemic circulation while also minimizing off-target toxicity. There is a stark difference between the number of preclinical trials of cancer nanomedicine and the clinical translation of the same. Despite the advantages proposed by the preclinical studies, the major hurdles of delivering cancer drugs using nanoparticles, micelles, or other nanostructures, are the biological, pharmaceutical or translational barriers. Membrane impermeability, endosomal and lysosomal escape, bloodstream stability, desired biodistribution profile, drug release and elimination kinetics and production costs along with patient compliance are some of the major hindrances. To tackle these translational challenges, there have been efforts to develop smart innovative drug delivery materials and therapeutic strategies. In this issue we aim to address the current stagnancy in cancer nanomedicine with the focus on how researchers are trying to (i) improve therapeutic window of the already approved drug, (ii) understand nano-bio interaction, (iii) break the current asymptote of the cancer nanomedicine, and (iv) improve clinical translatability and patient compliance.
Dr. Soumen Saha
Dr. Uttara Basu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- approved drugs
- repurposing old drugs
- nano-bio interaction
- advanced biomaterials
- clinical translation
